AbbVie’s Skyrocketing Sales: The Pillars of Growth and Investor Enthusiasm
AbbVie reported strong first-quarter revenue of $13.3 billion, an 8% increase from the previous year, driven by its immunology drugs Skyrizi and Rinvoq. The company’s stock rose over 3%, outpacing the broader S&P 500 index, thanks to impressive sales growth and strategic planning. Despite a slight dip in net income, adjusted profitability exceeded expectations, showcasing … Read more